心衰中的炎症-课件，幻灯， (英文）.ppt

* Simvastatin reduces TNF-α expression in myocardium Zhang JY, Cheng X, Liao YH, et al. Cardiovasc Drug Ther. 2005;19:13-21 MI MI-S Non MI area MI area * *P0.01 vs Sham # P0.01 vs MI-C Simvastatin modulate cytokines protein expression after AMI Zhang JY, Cheng X, Liao YH, et al. Cardiovasc Drug Ther. 2005; 19(1): 13-21 * Heart function improved in AMI rats after simvastatin treatment Groups n LVEDd (mm) EF (%) FS (%) Sham 10 4.5±0.3 85.2±3.7 51.6±3.1 MI-C 12 7.5±0.4* 41.4±4.3* 20.5±2.5* MI-S 12 5.9±0.3# 51.8±4.3# 25.4±2.7# Sham MI-C MI-S ED ES Compared with sham group, *p0.01 Compared with MI-C,#p0.05 Simvastatin animal trial after AMI Zhang JY, Cheng X, Liao YH, et al. Cardiovasc Drug Ther. 2005; 19(1): 13-21 * Summary(1) Inflammatory mechanism in heart failure Isoproterenol induced proinflammatory cytokine expression in myocardium Ang II-induced myocardial TNF-αbiosynthesis in heart Network between Ang II and TGF-β1 in mediating cardiac hypertrophy via auto-/paracrine mechanisms * Summary(2) Inflammatory intervention in heart failure Immunosuppression and anti-cytokine therapy were not satisfying TNF-α isn’t therapy target in heart failure because TNF-α expressed on the myocardial cells with heart failure Beta-blockers and Statins could regulate inflammation and improve heart function after AMI * Cognitive process of pathophysiology and therapy in haert failure Fluid retention Hemodynamic abnormity Neurohormone abnormity Cytokines 40-60 era 70-80 era 80-90 era 90 era Neurohormone antagonist Expand vessel /cardiotonic Diuretic Regulate of the immune function may become a new targeted therapy for the prevention of heart failure ？ Immune regulation * 1980 武汉协和医院 心血管病研究所 Acknowledgement The grant supported by NSFC Prof. Wang Zhao-Hui Accessory-prof. Wang Zhaohui Dr.Cheng Xiang Dr. Li Bin Dr. Zhang Jinying Dr.Tao Rong Dr. Ge Hong-Xia Dr. Liu Ying Researcher. Wang Min Dr. Guo Zhang-Qiang * The advance of therapy is following pathophysiology